Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Mining Human Prostate Cancer Datasets: The "camcAPP" Shiny App.

Dunning MJ, Vowler SL, Lalonde E, Ross-Adams H, Boutros P, Mills IG, Lynch AG, Lamb AD.

EBioMedicine. 2017 Mar;17:5-6. doi: 10.1016/j.ebiom.2017.02.022. Epub 2017 Mar 2. No abstract available.

2.

HNF1B variants associate with promoter methylation and regulate gene networks activated in prostate and ovarian cancer.

Ross-Adams H, Ball S, Lawrenson K, Halim S, Russell R, Wells C, Strand SH, Ørntoft TF, Larson M, Armasu S, Massie CE, Asim M, Mortensen MM, Borre M, Woodfine K, Warren AY, Lamb AD, Kay J, Whitaker H, Ramos-Montoya A, Murrell A, Sørensen KD, Fridley BL, Goode EL, Gayther SA, Masters J, Neal DE, Mills IG.

Oncotarget. 2016 Nov 15;7(46):74734-74746. doi: 10.18632/oncotarget.12543.

3.

A genetic study and meta-analysis of the genetic predisposition of prostate cancer in a Chinese population.

Marzec J, Mao X, Li M, Wang M, Feng N, Gou X, Wang G, Sun Z, Xu J, Xu H, Zhang X, Zhao SC, Ren G, Yu Y, Wu Y, Wu J, Xue Y, Zhou B, Zhang Y, Xu X, Li J, He W, Benlloch S, Ross-Adams H, Chen L, Li J, Hong Y, Kote-Jarai Z, Cui X, Hou J, Guo J, Xu L, Yin C, Zhou Y, Neal DE, Oliver T, Cao G, Zhang Z, Easton DF, Chelala C; PRACTICAL Consortium; CHIPGECS Group, Al Olama AA, Eeles RA, Zhang H, Lu YJ.

Oncotarget. 2016 Apr 19;7(16):21393-403. doi: 10.18632/oncotarget.7250.

4.

The Early Effects of Rapid Androgen Deprivation on Human Prostate Cancer.

Shaw GL, Whitaker H, Corcoran M, Dunning MJ, Luxton H, Kay J, Massie CE, Miller JL, Lamb AD, Ross-Adams H, Russell R, Nelson AW, Eldridge MD, Lynch AG, Ramos-Montoya A, Mills IG, Taylor AE, Arlt W, Shah N, Warren AY, Neal DE.

Eur Urol. 2016 Aug;70(2):214-8. doi: 10.1016/j.eururo.2015.10.042. Epub 2015 Nov 10.

5.

Integration of copy number and transcriptomics provides risk stratification in prostate cancer: A discovery and validation cohort study.

Ross-Adams H, Lamb AD, Dunning MJ, Halim S, Lindberg J, Massie CM, Egevad LA, Russell R, Ramos-Montoya A, Vowler SL, Sharma NL, Kay J, Whitaker H, Clark J, Hurst R, Gnanapragasam VJ, Shah NC, Warren AY, Cooper CS, Lynch AG, Stark R, Mills IG, Grönberg H, Neal DE; CamCaP Study Group.

EBioMedicine. 2015 Jul 29;2(9):1133-44. doi: 10.1016/j.ebiom.2015.07.017. eCollection 2015 Sep.

6.

HES5 silencing is an early and recurrent change in prostate tumourigenesis.

Massie CE, Spiteri I, Ross-Adams H, Luxton H, Kay J, Whitaker HC, Dunning MJ, Lamb AD, Ramos-Montoya A, Brewer DS, Cooper CS, Eeles R; UK Prostate ICGC Group, Warren AY, Tavaré S, Neal DE, Lynch AG.

Endocr Relat Cancer. 2015 Apr;22(2):131-44. doi: 10.1530/ERC-14-0454. Epub 2015 Jan 5.

7.

Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.

Bon H, Wadhwa K, Schreiner A, Osborne M, Carroll T, Ramos-Montoya A, Ross-Adams H, Visser M, Hoffmann R, Ahmed AA, Neal DE, Mills IG.

Mol Cancer Res. 2015 Apr;13(4):620-35. doi: 10.1158/1541-7786.MCR-13-0182-T. Epub 2014 Dec 29.

8.

HES6 drives a critical AR transcriptional programme to induce castration-resistant prostate cancer through activation of an E2F1-mediated cell cycle network.

Ramos-Montoya A, Lamb AD, Russell R, Carroll T, Jurmeister S, Galeano-Dalmau N, Massie CE, Boren J, Bon H, Theodorou V, Vias M, Shaw GL, Sharma NL, Ross-Adams H, Scott HE, Vowler SL, Howat WJ, Warren AY, Wooster RF, Mills IG, Neal DE.

EMBO Mol Med. 2014 May;6(5):651-61. doi: 10.1002/emmm.201303581.

9.

Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression.

Kote-Jarai Z, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Dadaev T, Jugurnauth-Little S, Ross-Adams H, Al Olama AA, Benlloch S, Halim S, Russell R, Dunning AM, Luccarini C, Dennis J, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock S, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah P, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D, Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L, Brenner H, Park JY, Kaneva R, Batra J, Spurdle A, Clements JA, Teixeira MR, Govindasami K, Guy M, Wilkinson RA, Sawyer EJ, Morgan A, Dicks E, Baynes C, Conroy D, Bojesen SE, Kaaks R, Vincent D, Bacot F, Tessier DC; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium, Easton DF, Eeles RA.

Hum Mol Genet. 2013 Jun 15;22(12):2520-8. doi: 10.1093/hmg/ddt086. Epub 2013 Mar 27. Erratum in: Hum Mol Genet. 2013 Oct 15;22(20):4239. Russel, Roslin [corrected to Russell, Roslin].

10.

Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis.

Grisanzio C, Werner L, Takeda D, Awoyemi BC, Pomerantz MM, Yamada H, Sooriakumaran P, Robinson BD, Leung R, Schinzel AC, Mills I, Ross-Adams H, Neal DE, Kido M, Yamamoto T, Petrozziello G, Stack EC, Lis R, Kantoff PW, Loda M, Sartor O, Egawa S, Tewari AK, Hahn WC, Freedman ML.

Proc Natl Acad Sci U S A. 2012 Jul 10;109(28):11252-7. doi: 10.1073/pnas.1200853109. Epub 2012 Jun 22.

11.

Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic stroke.

International Stroke Genetics Consortium (ISGC); Wellcome Trust Case Control Consortium 2 (WTCCC2), Bellenguez C, Bevan S, Gschwendtner A, Spencer CC, Burgess AI, Pirinen M, Jackson CA, Traylor M, Strange A, Su Z, Band G, Syme PD, Malik R, Pera J, Norrving B, Lemmens R, Freeman C, Schanz R, James T, Poole D, Murphy L, Segal H, Cortellini L, Cheng YC, Woo D, Nalls MA, Müller-Myhsok B, Meisinger C, Seedorf U, Ross-Adams H, Boonen S, Wloch-Kopec D, Valant V, Slark J, Furie K, Delavaran H, Langford C, Deloukas P, Edkins S, Hunt S, Gray E, Dronov S, Peltonen L, Gretarsdottir S, Thorleifsson G, Thorsteinsdottir U, Stefansson K, Boncoraglio GB, Parati EA, Attia J, Holliday E, Levi C, Franzosi MG, Goel A, Helgadottir A, Blackwell JM, Bramon E, Brown MA, Casas JP, Corvin A, Duncanson A, Jankowski J, Mathew CG, Palmer CN, Plomin R, Rautanen A, Sawcer SJ, Trembath RC, Viswanathan AC, Wood NW, Worrall BB, Kittner SJ, Mitchell BD, Kissela B, Meschia JF, Thijs V, Lindgren A, Macleod MJ, Slowik A, Walters M, Rosand J, Sharma P, Farrall M, Sudlow CL, Rothwell PM, Dichgans M, Donnelly P, Markus HS.

Nat Genet. 2012 Feb 5;44(3):328-33. doi: 10.1038/ng.1081.

12.

The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine.

Whitaker HC, Kote-Jarai Z, Ross-Adams H, Warren AY, Burge J, George A, Bancroft E, Jhavar S, Leongamornlert D, Tymrakiewicz M, Saunders E, Page E, Mitra A, Mitchell G, Lindeman GJ, Evans DG, Blanco I, Mercer C, Rubinstein WS, Clowes V, Douglas F, Hodgson S, Walker L, Donaldson A, Izatt L, Dorkins H, Male A, Tucker K, Stapleton A, Lam J, Kirk J, Lilja H, Easton D; IMPACT Study Steering Committee; IMPACT Study Collaborators; UK GPCS Collaborators, Cooper C, Eeles R, Neal DE.

PLoS One. 2010 Oct 13;5(10):e13363. doi: 10.1371/journal.pone.0013363.

13.

Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke.

Gschwendtner A, Bevan S, Cole JW, Plourde A, Matarin M, Ross-Adams H, Meitinger T, Wichmann E, Mitchell BD, Furie K, Slowik A, Rich SS, Syme PD, MacLeod MJ, Meschia JF, Rosand J, Kittner SJ, Markus HS, Müller-Myhsok B, Dichgans M; International Stroke Genetics Consortium.

Ann Neurol. 2009 May;65(5):531-9. doi: 10.1002/ana.21590.

14.

Paraoxonase gene polymorphisms and haplotype analysis in a stroke population.

Pasdar A, Ross-Adams H, Cumming A, Cheung J, Whalley L, St Clair D, MacLeod MJ.

BMC Med Genet. 2006 Mar 21;7:28.

Supplemental Content

Loading ...
Support Center